Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
ObjectiveTo test whether autologous modified mesenchymal stem cells (MSCs) improve recovery in patients with chronic major stroke. MethodsIn this prospective, open-label, randomized controlled trial with blinded outcome evaluation, patients with severe middle cerebral artery territory infarct within 90 days of symptom onset were assigned, in a 2:1 ratio, to receive preconditioned autologous MSC injections (MSC group) or standard treatment alone (control group). The primary outcome was the score on the modified Rankin Scale (mRS) at 3 months. The secondary outcome was to further demonstrate motor recovery. ResultsA total of 39 and 15 patients were included in the MSC and control groups, respectively, for the final intention-to-treat analysis. Mean age of patients was 68 (range 28–83) years, and mean interval between stroke onset to randomization was 20.2 (range 5–89) days. Baseline characteristics were not different between groups. There was no significant difference between the groups in the mRS score shift at 3 months (p = 0.732). However, secondary analyses showed significant improvements in lower extremity motor function in the MSC group compared to the control group (change in the leg score of the Motricity Index, p = 0.023), which was notable among patients with low predicted recovery potential. There were no serious treatment-related adverse events. ConclusionsIV application of preconditioned, autologous MSCs with autologous serum was feasible and safe in patients with chronic major stroke. MSC treatment was not associated with improvements in the 3-month mRS score, but we did observe leg motor improvement in detailed functional analyses. Classification of EvidenceThis study provides Class III evidence that autologous MSCs do not improve 90-day outcomes in patients with chronic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance
Fugl-Meyer, A., Jääskö, L., Leyman, I., Olsson, S., & Steglind, S. (1975) · Journal of Rehabilitation Medicine · doi:10.2340/1650197771331 · Cited by 5,564
Rossini, P. M., Barker, A. T., Berardelli, A., Caramia, M. D., Caruso, G., Cracco, R. Q., Dimitrijević, M. R., Hallett, M., Katayama, Y., Lücking, C. H., et al. (1994) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(94)90029-9 · Cited by 3,030 · cited 1×
“was classified as MEPs response and no MEPs response, which did not exhibit any MEP with peak-to-peak amplitude of ≥50 μV in the affected first dorsal interosseous according to 3 successive discharges with maximal stimulator output, as previously described.(21)”
MethodClinical Gait Assessment in the Neurologically Impaired
Holden, M. K., Gill, K. M., Magliozzi, M. R., Nathan, J., & Piehl-Baker, L. (1984) · Physical Therapy · doi:10.1093/ptj/64.1.35 · Cited by 1,499
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials
Saver, J. L., & Gornbein, J. (2009) · Neurology · doi:10.1212/01.wnl.0000341308.73506.b7 · Cited by 135
Research works printed but not linked: 35
- 10.1016/S1474-4422(02)00040-6 · DOI · Paper page
- 10.1002/stem.430 · DOI · Paper page
- 10.3727/096368908786991551 · DOI
- 10.1161/STROKEAHA.109.568881 · DOI · Paper page
- 10.1093/brain/awr063 · DOI · Paper page
- 10.3727/096368916X690430 · DOI
- 10.1007/s12975-017-0538-2 · DOI
- 10.1177/0963689718755404 · DOI
- 10.1186/1745-6215-14-317 · DOI · Paper page
- 10.1002/ana.20501 · DOI · Paper page
- 10.1159/000115178 · DOI · Paper page
- 10.1016/j.apmr.2007.06.764 · DOI · Paper page
- 10.1002/ana.24472 · DOI · Paper page
- Hawe RL, Scott SH, Dukelow SP. Taking proportional out of stroke recovery. Stroke Epub 2018 Dec 7.
- 10.1093/brain/aws146 · DOI · Paper page
- 10.1002/acn3.488 · DOI · Paper page
- 10.1310/tsr18s01-599 · DOI · Paper page
- 10.1179/1945511915Y.0000000003 · DOI
- 10.1016/j.nicl.2013.04.002 · DOI
- 10.3109/03790798909166398 · DOI
- 10.1161/STROKEAHA.108.533208 · doi:10.1161/strokeaha.108.533208
- 10.1161/STROKEAHA.110.601914 · DOI · Paper page
- 10.1001/jama.2016.13647 · DOI · Paper page
- 10.1093/jnen/63.1.84 · DOI · Paper page
- 10.1161/STROKEAHA.112.679605 · DOI
- 10.3727/096368913X674666 · DOI
- 10.1016/S1474-4422(17)30046-7 · DOI · Paper page
- 10.1089/scd.2016.0268 · DOI
- 10.1038/sj.jcbfm.9600217 · DOI · Paper page
- 10.1089/scd.2012.0037 · DOI
- 10.1002/sctm.18-0236 · DOI
- 10.1016/j.ymthe.2004.02.012 · DOI · Paper page
- 10.1089/10430340260201699 · DOI · Paper page
- 10.1016/j.jcyt.2013.05.020 · DOI
- 10.1161/01.STR.0000141680.49960.d7 · DOI · Paper page
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Wang, Y., Niu, H., Li, L., Han, J., Liu, Z., Chu, M., Sha, X., & Zhao, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01862-x · Cited by 172
Yarahmadi, A., Dorri Giv, M., Hosseininejad, R., Rezaie, A., Mohammadi, N., Afkhami, H., & Farokhi, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472679 · Cited by 21
Amadeo, F., Trivino Cepeda, K., Littlewood, J., Wilm, B., Taylor, A., & Murray, P. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210013 · Cited by 20
Metadata
- Authors
- Chung, J.-W., Chang, W. H., Bang, O. Y., Moon, G. J., Kim, S. J., Kim, S.-K., Lee, J. S., Sohn, S.-I., Kim, Y.-H., & Collaborators, F. T. S.-2.
- Venue
- Neurology
- Published
- 2021-02-16
- Volume
- 96
- Issue
- 7
- Pages
- e1012-e1023
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3125304137
- Cited by
- 200
- References
- 4
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke. https://app.cochat.ai/papers/10.1212/wnl.0000000000011440
- The paper
- Chung, J.-W., Chang, W. H., Bang, O. Y., Moon, G. J., Kim, S. J., Kim, S.-K., Lee, J. S., Sohn, S.-I., Kim, Y.-H., & Collaborators, F. T. S.-2. (2021). Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke. Neurology. https://doi.org/10.1212/wnl.0000000000011440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.